PGPEP1L: A Potential Drug Target and Biomarker (G145814)

Target Name: PGPEP1L

NCBI ID: G145814

PGPEP1L

PGPEP1L: A Potential Drug Target and Biomarker

Glutamyl-peptidase 1-like protein (PGPEP1L) is a protein that is expressed in various tissues and cell types in the human body. It is a member of the serine proteases superfamily and is characterized by its catalytic activity towards the peptide bond. PGPEP1L is involved in the regulation of various cellular processes, including cell signaling, inflammation, and neurodegeneration.

The development and progression of many diseases, including cancer, neurodegenerative disorders, and autoimmune diseases, are influenced by the function and dysfunction of PGPEP1L. Therefore, the study of PGPEP1L has great implications for the development of new therapeutic approaches. As a potential drug target and biomarker, PGPEP1L is of interest to researchers because of its potential role in the treatment of diseases that are characterized by the dysfunction of this protein.

Drug Targets

PGPEP1L has been identified as a potential drug target due to its unique catalytic activity and its involvement in various cellular processes. Several studies have demonstrated that inhibition of PGPEP1L can lead to the inhibition of cellular processes that are critical for the development and progression of diseases. For example, several studies have shown that the inhibition of PGPEP1L can lead to the inhibition of cancer cell growth, invasion, and metastasis.

In addition, PGPEP1L has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the dysfunction of PGPEP1L and its downstream targets. Therefore, inhibition of PGPEP1L has been shown to be a potential therapeutic approach for the treatment of neurodegenerative diseases.

Biomarkers

PGPEP1L has also been identified as a potential biomarker for the diagnosis and prognosis of various diseases. The levels of PGPEP1L have been shown to be elevated in the brains of individuals with Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Therefore, the detection of PGPEP1L levels in individuals with these diseases can be used as a biomarker for the diagnosis and prognosis of these conditions.

In addition, PGPEP1L has also been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and inflammation, and is a key factor in the development and progression of many diseases, including cancer. Therefore, the regulation of PGPEP1L by TGF-β signaling pathway is a potential biomarker for the diagnosis and prognosis of various diseases.

Conclusion

PGPEP1L is a protein that is involved in various cellular processes and has been shown to be involved in the development and progression of many diseases. As a potential drug target and biomarker, PGPEP1L is of interest to researchers because of its potential role in the treatment of these diseases. Further research is needed to fully understand the function and dysfunction of PGPEP1L, and to develop new therapeutic approaches based on its unique properties.

Protein Name: Pyroglutamyl-peptidase I Like

The "PGPEP1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGPEP1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets